comparemela.com

Latest Breaking News On - ஜான் மகிநொந் - Page 4 : comparemela.com

Zespri s contentious China deal rejected by regulator over IP leakage and China relationship concerns

GERARD HUTCHING/STUFF Bringing it all back home - Zespri shares kiwifruit pointers with Chinese growers. This video was first published in 2018. Zespri s contentious China deal was rejected by the industry regulator due to concerns intellectual property would leak into China, and the company’s relationship with its largest market could be damaged. An independent assessment of the kiwifruit giant s China project – a trial of buying and branding counterfeit SunGold kiwifruit grown in China – also canvassed a “wider geo-political risk”, but further details have been redacted in documents obtained by Stuff. China expert Anne-Marie Brady​ says references to geo-political risk show China considers the proposal a political relationship, not a business relationship, risking the banning of exports if offence is caused.

Get informed on the top stories of the day in one quick scan

Injured woman secretly videotaped by insurer, then wrongly accused of fraud

Injured woman secretly videotaped by insurer, then wrongly accused of fraud An Ontario woman was secretly followed and videotaped by the organization that should have been helping her recover from a workplace injury. Instead, Ontario s Workplace Safety and Insurance Board tried to use the videos to discredit her. Experts say all kinds of insurers use covert surveillance to intimidate claimants or discredit claims. Social Sharing

Henry Ford Health System ends hydroxychloroquine study

Credit Adobe Stock Promoted in April as the first large-scale drug study on the effectiveness of hydroxychloroquine to protect against COVID-19, the Detroit-based clinical trial has quietly been iced. Henry Ford Health System officials told Bridge Michigan they could not find enough participants to continue studying whether the drug could help beat back the deadly pandemic. Hydroxychloroquine an antimalarial drug that has also proven useful in treating rheumatoid arthritis, lupus, and other inflammatory diseases briefly produced some excitement last spring when it was promoted as a potential game-changer by President Trump. But early optimism gave way to broader medical studies, with the nation’s top health agencies eventually determining it was not effective in treating or preventing the spread of the novel coronavirus.    

Henry Ford study on hydroxychloroquine for COVID-19 quietly shut down

Henry Ford study on hydroxychloroquine for COVID-19 quietly shut down By Robin Erb, Bridge Michigan © GERARD JULIEN, AFP via Getty Images Hydroxychloroquine, an antimalarial drug dubbed a gift from God by US President Donald Trump for its potential ability to fight the new coronavirus, was found to be no more effective than standard treatment in a small Chinese study. Promoted in April as the first large-scale drug study on the effectiveness of hydroxychloroquine to protect against COVID-19, the Detroit-based clinical trial has quietly been iced. Henry Ford Health System officials told Bridge Michigan they could not find enough participants to continue studying whether the drug could help beat back the deadly pandemic. 

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.